Press

  • aside

    Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal…

    by
  • aside

    From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study…

    by
  • aside

    Isofols appoints Sven Erickson as Chief Commercial Officer

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of  Sven Erickson as Chief…

    by
  • aside

    Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera,…

    by
  • aside

    Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking…

    by
  • aside

    Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol…

    by